Publications

BibTex format

@article{Harbaum:2021:10.1111/bph.15056,
author = {Harbaum, L and Rhodes, CJ and Otero-Núñez, P and Wharton, J and Wilkins, MR},
doi = {10.1111/bph.15056},
journal = {British Journal of Pharmacology},
pages = {108--120},
title = {The application of 'omics' to pulmonary arterial hypertension},
url = {http://dx.doi.org/10.1111/bph.15056},
volume = {178},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Recent genome-wide analyses of rare and common sequence variations have brought greater clarity to the genetic architecture of pulmonary arterial hypertension and implicated novel genes in disease development. Transcriptional signatures have been reported in whole lung tissue, pulmonary vascular cells and peripheral circulating cells. High-throughput platforms for plasma proteomics and metabolomics have identified novel biomarkers associated with clinical outcomes and provided molecular instruments for risk assessment. There are methodological challenges to integrating these datasets, coupled to statistical power limitations inherent to the study of a rare disease, but the expectation is that this strategy will reveal novel druggable targets and biomarkers that will open the way to personalised medicine. Here we review the current state-of-the-art and future promise of "omics" in the field of translational medicine in pulmonary arterial hypertension.
AU  - Harbaum,L
AU  - Rhodes,CJ
AU  - Otero-Núñez,P
AU  - Wharton,J
AU  - Wilkins,MR
DO  - 10.1111/bph.15056
EP  - 120
PY  - 2021///
SN  - 0007-1188
SP  - 108
TI  - The application of 'omics' to pulmonary arterial hypertension
T2  - British Journal of Pharmacology
UR  - http://dx.doi.org/10.1111/bph.15056
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32201940
UR  - http://hdl.handle.net/10044/1/78022
VL  - 178
ER  -

Download

DrChristopherRhodes

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)